After a series of significant corporate appointments, Mind Cure is poised to advance its operations.
Mind Cure's latest addition to its Scientific Advisory Board is a noted expert in psychedelic medicine, published researcher, and professor of pharmacology.
Field Trip Psychedelics is targeting a $16 billion treatment market with its ketamine-assisted psychotherapy clinics.
Dr. Dan Engle, a leading voice in psychedelic medicine, has been appointed by Mind Cure (CSE:MCUR) as a scientific advisor
The company bolsters its executive team with the addition of an industry leader and experienced entrepreneur